Low Grade Serous Ovarian Carcinoma Epidemiology Forecast

Key Highlights

 

• According to Surveillance, Epidemiology, and End Results (SEER), the rate of new cases of ovarian cancer was 10.6 per 100,000 women per year. In 2019, there were an estimated 233,565 women living with ovarian cancer in the United States.

 

• As per Monk et al. (2019), ~10% of cases of serous ovarian cancer are low grade. About 60% of low-grade serous cancers are associated with a borderline component at the time of diagnosis. Women with low-grade serous ovarian cancer are typically diagnosed at a younger age (55.5 years vs. 62.6 years for high-grade serous) and do not harbor p53 mutations.

 

• Low-Grade Serous Ovarian Carcinoma epidemiology [segmented as Total Prevalent Cases of Ovarian Cancer, Type-specific (Serous) Prevalent Cases of Ovarian Carcinoma, Grade-specific Prevalent Cases of Serous Ovarian Carcinoma, Mutation-specific Prevalent Cases of Serous Ovarian Carcinoma, Stage-specific Prevalent Cases of Low-Grade Serous Ovarian Carcinoma, and Treatable Cases of Low-Grade Serous Ovarian Carcinoma] in the Low-Grade Serous Ovarian Carcinoma epidemiology report.

 

Request for unlocking of Low-Grade Serous Ovarian Carcinoma Epidemiology

 

DelveInsight's ‘Low-Grade Serous Ovarian Carcinoma Epidemiology Forecast — 2034’ report delivers an in-depth understanding of the disease, historical and forecasted Low-Grade Serous Ovarian Carcinoma epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

 

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

 

Study Period: 2021-2034

 

Low-Grade Serous Ovarian Carcinoma Epidemiology Disease Understanding

The DelveInsight’s Low-Grade Serous Ovarian Carcinoma market report gives a thorough understanding of Low-Grade Serous Ovarian Carcinoma by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. Low-grade serous ovarian carcinoma (LGSOC) is an uncommon (<5%) and under-investigated ovarian cancer type, in some cases arising from serous borderline tumors. In contrast to high grade serous ovarian cancers (HGSOCs), Low-grade serous ovarian carcinomas are TP53 wild-type, do not demonstrate genomic instability or homologous recombination repair deficiency and frequently harbor classical activating mutations in canonical MAPK pathway components (KRAS, BRAF and NRAS). Low-Grade Serous Ovarian Carcinomas typically display high estrogen receptor (ER) expression, with expression of progesterone receptor (PR) in a subset of cases.

 

Histologically, Low-grade serous ovarian carcinoma is characterized by a monotonous proliferation of cuboidal, low columnar cells, mild to moderate atypia without nuclear pleomorphism, mitotic index up to 12 mitoses per 10 high power fields (HPF), and destructive invasion.

 

Low-Grade Serous Ovarian Carcinoma Diagnosis

Low-grade serous ovarian carcinoma is diagnosed using clinical examination which may include a pelvic examination, ultrasound, and CT scans. You should be offered a CA125 blood test which can detect a protein in the blood that is a cancer marker.

Low-Grade Serous Ovarian Carcinoma is generally categorized into grades as, Pilocytic Low-Grade Serous Ovarian Carcinoma, Pleomorphic XantoLow-Grade Serous Ovarian Carcinoma and Sub ependymal Giant Cell Low-Grade Serous Ovarian Carcinoma (SEGA) in Grade 1, Diffuse Low-Grade Serous Ovarian Carcinoma in Grade 2, Anaplastic Low-Grade Serous Ovarian Carcinoma in Grade 3, and Glioblastoma (GBM) in Grade 4.

 

Low-Grade Serous Ovarian Carcinoma Epidemiology

The Low-Grade Serous Ovarian Carcinoma epidemiology section provides insights about historical and current Low-Grade Serous Ovarian Carcinoma patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

 

• According to Surveillance, Epidemiology, and End Results (SEER), the rate of new cases of ovarian cancer was 10.6 per 100,000 women per year. In 2019, there were an estimated 233,565 women living with ovarian cancer in the United States.

 

• As per Monk et al. (2019), ~10% of cases of serous ovarian cancer are low grade. About 60% of low-grade serous cancers are associated with a borderline component at the time of diagnosis. Women with low-grade serous ovarian cancer are typically diagnosed at a younger age (55.5 years vs. 62.6 years for high-grade serous) and do not harbor p53 mutations.

 

• The disease epidemiology covered in the report provides historical as well as forecasted Low-Grade Serous Ovarian Carcinoma epidemiology [segmented as Total Prevalent Cases of Ovarian Cancer, Type-specific (Serous) Prevalent Cases of Ovarian Carcinoma, Grade-specific Prevalent Cases of Serous Ovarian Carcinoma, Mutation-specific Prevalent Cases of Serous Ovarian Carcinoma, Stage-specific Prevalent Cases of Low-Grade Serous Ovarian Carcinoma, and Treatable Cases of Low-Grade Serous Ovarian Carcinoma] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2021 to 2034.

 

Country Wise- Low-Grade Serous Ovarian Carcinoma Epidemiology

This section provides glimpse of the Low-Grade Serous Ovarian Carcinoma epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

 

KOL- Views

To keep up with the current Low-Grade Serous Ovarian Carcinoma patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the Low-Grade Serous Ovarian Carcinoma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.

 

Learn how the therapeutic market will evolve and grow in the coming years: Low-Grade Serous Ovarian Carcinoma Market
 

Scope of the Low-Grade Serous Ovarian Carcinoma Epidemiology Report

• The report covers the descriptive overview of Low-Grade Serous Ovarian Carcinoma, explaining their causes, symptoms, pathophysiology, and genetic basis
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan
• The report assesses the disease risk and burden and highlights the unmet needs of Low-Grade Serous Ovarian Carcinoma
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population
• The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of Ovarian Cancer, Type-specific (Serous) Prevalent Cases of Ovarian Carcinoma, Grade-specific Prevalent Cases of Serous Ovarian Carcinoma, Mutation-specific Prevalent Cases of Serous Ovarian Carcinoma, Stage-specific Prevalent Cases of Low-Grade Serous Ovarian Carcinoma, and Treatable Cases of Low-Grade Serous Ovarian Carcinoma

 

Low-Grade Serous Ovarian Carcinoma Epidemiology Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Low-Grade Serous Ovarian Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition     
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Low-Grade Serous Ovarian Carcinoma
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

Low-Grade Serous Ovarian Carcinoma Report Insights

• Patient Population
• Therapeutic Approaches

 

Low-Grade Serous Ovarian Carcinoma Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Low-Grade Serous Ovarian Carcinoma Epidemiology Segmentation

 

Low-Grade Serous Ovarian Carcinoma Report Assessment

• Disease Understanding
• Current Diagosis Practices and Guidelines
• Epidemiology Trends

 

Key Questions

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Low-Grade Serous Ovarian Carcinoma?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Low-Grade Serous Ovarian Carcinoma patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Low-Grade Serous Ovarian Carcinoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM concerning the patient population about Low-Grade Serous Ovarian Carcinoma?
• Out of all 7MM countries, which country would have the highest prevalent population of Low-Grade Serous Ovarian Carcinoma during the forecast period (2025-2034)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2025-2034)?

 

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Low-Grade Serous Ovarian Carcinoma Disease market
• To understand the future market competition in the Low-Grade Serous Ovarian Carcinoma Disease market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Low-Grade Serous Ovarian Carcinoma Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the Low-Grade Serous Ovarian Carcinoma Disease market
• To understand the future market competition in the Low-Grade Serous Ovarian Carcinoma Disease market